Evolus
EOLS6.1900.16% ( +0.010 )
Evolus (EOLS)
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Je...
- Open
- 6.210
- High
- 6.410
- Low
- 6.105
- Prev. Close
- 6.180
- Volume
- 301.13K
- Turnover
- 1.87M
- Avg Price
- 6.205
- Bid/Ask Ratio
- --
- Amplitude
- 4.94%
- 52wk High
- 9.580
- Volume Ratio
- 0.80
- Turnover Ratio
- 0.60%
Evolus Analyst Rating
View MoreForecast & Rating
Jul 20, 2026Price forecast
$14.67136.94%
Forecast & RatingStrong buy
7analysts
- Strong buy71.43%
- Buy14.29%
- Hold14.29%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 22 at 07:30 AM
Evolus to report second-quarter results after markets close, host conference call
- Unusual Whales · Jul 10 at 03:17 PM
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- PUBT · Jul 8 at 08:02 AM
Evolus partners with IBSA to license, distribute Profhilo in US
- Tip Ranks · Jun 8 at 03:55 PM
Evolus (EOLS) Receives a Buy from Mizuho Securities
- prnewswire · May 22 at 09:33 AM
10:31 ETRegenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It
- Unusual Whales · May 11 at 07:34 AM
Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe
